Hypothyroidism.
Level 5 - mechanism / opinion, no new human data
Narrative review / clinical seminar without systematic review methodology
PubMed 39368843 · doi:10.1016/S0140-6736(24)01614-3
What was done
This Lancet Seminar reviewed the epidemiology, genetic determinants, causes, clinical presentations, diagnostic criteria, and management strategies for hypothyroidism. The authors synthesized evidence on standard biochemical testing, individualized reference ranges based on age, sex, and pregnancy, standard levothyroxine therapy, and alternative treatments such as liothyronine or desiccated thyroid extract.
What was found
The abstract reports that standard levothyroxine monotherapy effectively normalizes thyroid function tests and improves symptoms for the majority of patients. However, 10% of patients experience persistent symptoms of ill health despite biochemical normalization, and a substantial proportion of patients on levothyroxine maintain thyroid-stimulating hormone concentrations outside target reference ranges. No other quantitative figures or comparative effect sizes are provided in the abstract.
Why it matters
This review synthesizes ongoing debates regarding individualized diagnostic thresholds and treatment strategies for patients who remain symptomatic despite receiving standard levothyroxine replacement.
Limits
The abstract describes a broad narrative seminar rather than a systematic review with defined search criteria or meta-analytic data synthesis. It provides no new primary data, risk estimates, or quantitative comparisons between different replacement therapies.
Cited by
- context Eighty to ninety percent of women diagnosed with hypothyroidism have Hashimoto's thyroiditis.